Trial Profile
A study assessing COVID-HIG for the treatment for severe hospitalized patients as well as protection for at-risk individuals
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 06 Apr 2020
Price :
$35
*
At a glance
- Drugs COVID-2019 immune globulins (Human) (Primary)
- Indications COVID 2019 infections
- Focus Therapeutic Use
- 02 Apr 2020 According to an Emergent BioSolutions media release, company and the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), have agreed to incorporate the company COVID-HIG product candidate into one of NIAID clinical studies for assessment of treatments for COVID-19 once clinical material is available, and the study begins.
- 26 Mar 2020 New trial record
- 11 Mar 2020 According to an Emergent BioSolutions media release, this study is expected to begin as early as the third quarter of 2020.